Buffett’s Berkshire Expands Empire with $9.7 Billion OxyChem Buy

Picture this: The market’s quiet, deals are scarce, and most investors are hoarding cash waiting for the next big wave. Then, out of nowhere, Warren Buffett makes a move that has Wall Street buzzing again. Berkshire Hathaway drops $9.7 billion in cash to scoop up Occidental Petroleum’s chemical arm, OxyChem, a deal that feels less like a reaction and more like a calculated bet on where American industry is heading next. It’s a story that isn’t just about a sale or a balance-sheet cleanup. It’s about timing, legacy, and the kind of patient conviction that turns good companies into generational empires. And as Buffett prepares to hand over the reins to Greg Abel, this move might just tell us how Berkshire plans to play the next decade of growth

The Deal That’s Shaking Up Wall Street

Berkshire Hathaway’s acquisition of OxyChem is Buffett’s biggest purchase since 2022, when he snapped up Alleghany for $11.6 billion. The deal is expected to close in the fourth quarter of 2025 and will make OxyChem a fully owned subsidiary of Berkshire.  OxyChem, known for producing chlorine, vinyl chloride, and calcium chloride, materials vital for water treatment, plastics, and healthcare, wasn’t exactly thriving. Occidental had even cut its pre-tax income forecast by about 15%, citing a market surplus. Still, it’s a gem of a business that fits neatly into Berkshire’s industrial empire, right alongside Lubrizol, the speciality chemicals company Buffett bought in 2011.

Occidental plans to use $6.5 billion of the proceeds to slash debt, trimming its principal obligations below $15 billion and cutting interest costs by nearly 30%. That’s like dropping a financial backpack full of bricks before sprinting into its next growth phase.

Occidental’s “No More Big Deals” Moment

After its $10.8 billion CrownRock acquisition in 2024 and the earlier $38.7 billion Anadarko takeover, Occidental was swimming in leverage. CEO Vicki Hollub put it bluntly: “I believe we are done with the big deals.” This sale is her mic-drop moment, shifting from empire-building to organic growth. The company fielded multiple offers but went with Berkshire’s all-cash bid for “certainty to close.” As Hollub put it, “We wanted an offer that had certainty, and now with a debt reduction, we’re where we need to be to get more value to shareholders faster.”

Old School Discipline Meets New Era Strategy

For Buffett, this deal is pure “win-win.” Berkshire already owns about 28% of Occidental’s stock, plus $8.5 billion in preferred shares paying 8% annual dividends, so helping Oxy pay down debt makes Buffett’s own investment stronger. It’s also a classic Buffett playbook move: buy an undervalued, cash-generating asset in a down cycle, then let time do the compounding. And with Greg Abel, his successor, now taking the lead, the deal also signals a smooth leadership handoff at Berkshire. Abel’s statement summed it up: “We’re acquiring a robust portfolio of operating assets supported by an accomplished team.” Even after writing this massive check, Berkshire’s $344 billion cash hoard barely blinks; less than 3% goes toward OxyChem. Talk about deep pockets.

Why Berkshire’s Betting Big on Chemicals

Simple: steady demand and resilience. Even with softer margins this year, OxyChem’s materials are the backbone of everyday life, from disinfecting water to making batteries and roads safer. Berkshire thrives on businesses that keep the lights on regardless of economic turbulence, and OxyChem fits that bill. Plus, Buffett knows this playbook well. Back in 2011, he made a similar move with Lubrizol, a deal that continues to pay steady dividends. Analysts say the acquisition diversifies Berkshire’s industrial holdings while giving it exposure to a sector tied closely to U.S. infrastructure and healthcare.

How the Numbers Stack Up

Let’s break it down:

• OxyChem 2025 forecast: pre-tax income between $800–$900 million, down 15% from prior expectations.
• Occidental’s net debt: expected to fall from 1.7x to 1.2x EBITDA post-sale.
• Debt reduction: $6.5 billion from this deal plus roughly $4 billion in other asset sales.
• Berkshire cash reserves: around $344 billion at mid-2025; even after the purchase, liquidity remains strong.
• Interest savings for Oxy: estimated $350 million per year after paying down principal debt.

Financially, it’s a reset for Oxy and a quiet power move for Berkshire, which barely dents its balance sheet while boosting its asset base. Sure, OxyChem’s near-term earnings may be muted, but analysts see long-term upside. As the global demand for water treatment, plastics, and healthcare materials rebounds, OxyChem could ride the next cycle higher, with Berkshire’s stability giving it the breathing room to grow. Meanwhile, Occidental can refocus on its core oil and gas operations and shareholder returns, potentially buying back stock and paying down debt faster. Buffett’s right-hand man, Greg Abel, known for operational efficiency during his tenure at Berkshire Hathaway Energy, is expected to apply the same rigour here, potentially unlocking synergies across Berkshire’s industrial units.

Wrapping it Up

This isn’t just another M&A headline; it’s a financial symphony of timing, patience, and precision. Occidental gets to clean up its books and rebuild focus, while Berkshire secures a durable asset that prints cash in any economy. It’s also a symbolic transition moment: Buffett handing off the baton to Abel with a big, confidence-building acquisition. As one analyst quipped, “It’s a win-win, but Buffett’s winning on both sides.” In the end, the $9.7 billion OxyChem play isn’t just a deal, it’s a statement: even at 95, Buffett’s not done teaching Wall Street how to play the long game.

Get your CPE Credit from here